Tanja Obradovic: Dostarlimab chemotherapy in primary advanced or recurrent endometrial cancer
Tanja Obradovic, Vice President, Oncology Scientific Affairs at ICON, shared on LinkedIn:
“Further inroads of PD-1 inhibitors into treatment of endometrial cancer came as FDA just granted priority review for label expansion to Dostarlimab. Under consideration will be expansion for Dostarlimab use in combination with chemotherapy (carboplatin or paclitaxel) in all adult patients with primary advanced or recurrent endometrial cancer. Under prior indication granted (based on RUBY trial analysis in 2023) Dostarlimab use in chemo combo was limited to patients with tumors that are with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) status.
To highlight more details on potentially eligible population. Patients in RUBY trial had histologically or cytologically confirmed primary advanced or recurrent (International Federation of Gynecology and Obstetrics [FIGO] stage III or IV) endometrial cancer that was not amenable to curative therapy.
Patients were required to have met one of the following inclusion criteria: primary advanced stage IIIA, IIIB, or IIIC1 disease that could be evaluated or measured with the use of Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, as determined by the investigator; primary advanced stage IIIC1 disease with carcinosarcoma, clear-cell, serous, or mixed histologic characteristics, regardless of the presence of disease that could be evaluated or measured; primary advanced stage IIIC2 or stage IV disease, regardless of the presence of disease that could be evaluated or measured; or disease that either was in its first recurrence and had not been treated with systemic therapy or had been treated with neoadjuvant or adjuvant systemic therapy and had recurred or progressed at least 6 months after completion of treatment (first recurrence). As across this population there is high need for treatment options.
With potential Dostarlimab label expansion meeting truly high medical need in many more endometrial cancer patients regardless of dMMR or MSI-H status may be coming.”
Source: Tanja Obradovic/LinkedIn